Overview

Carmustine Implants and O(6)-Benzylguanine in Treating Children With Recurrent Malignant Glioma

Status:
Terminated
Trial end date:
2004-07-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemotherapy placed into the surrounding tissue after surgery to remove the tumor may kill any remaining tumor cells. O(6)-benzylguanine may increase the effectiveness of carmustine by making tumor cells more sensitive to the drug. PURPOSE: Phase I trial to study the safety of combining O(6)-benzylguanine with carmustine implants in treating children who have recurrent malignant glioma.
Phase:
Phase 1
Details
Lead Sponsor:
Pediatric Brain Tumor Consortium
Collaborator:
National Cancer Institute (NCI)
Treatments:
Carmustine
O(6)-benzylguanine